Updates on Antibiotics for Common Adult Infections
Community-Acquired Pneumonia (CAP)
For non-severe CAP, treat for a minimum of 5 days if clinical stability is achieved, with emerging evidence supporting 3-day courses in select patients who stabilize by day 3 1, 2.
The 2019 ATS/IDSA guideline establishes that most patients achieve clinical stability within 48-72 hours, making 5 days appropriate for the majority 1. Clinical stability criteria include normalized vital signs (heart rate, respiratory rate, blood pressure, oxygen saturation, temperature), ability to eat, and normal mentation. However, newer 2025 evidence demonstrates that 3-day antibiotic courses are non-inferior for patients who achieve clinical stability by day 3 2. This personalized approach means:
- 3 days: Non-severe/moderate CAP stabilized at day 3
- 5 days: Stability achieved by day 5
- 7 days: Suspected/proven MRSA or P. aeruginosa, or other uncomplicated CAP not stabilized by day 5 1, 2
Empiric regimen selection: The guideline recommends macrolide + β-lactam or respiratory fluoroquinolone monotherapy for hospitalized non-severe CAP 1. Recent comparative data shows no mortality difference between these regimens (1.5-1.9%), with doxycycline + β-lactam emerging as an acceptable alternative when allergies or contraindications exist 3.
Critical caveat: Failure to achieve clinical stability within 5 days warrants assessment for resistant pathogens, complications (empyema, abscess), or alternative diagnoses 1.
Uncomplicated Urinary Tract Infections (UTIs)
First-line therapy for acute uncomplicated cystitis in non-pregnant women is nitrofurantoin 100 mg four times daily for 5 days, fosfomycin 3g single dose, or pivmecillinam 5-day course 4, 5.
Fluoroquinolones should be restricted and avoided as first-line empiric therapy due to high resistance rates (27% trimethoprim resistance documented in recent surveillance) 4, 6. Second-line options include oral cephalosporins (cephalexin, cefixime), amoxicillin-clavulanate, or fluoroquinolones only when susceptibility is confirmed 4, 5.
Duration:
- Uncomplicated cystitis: 3-5 days (fosfomycin single dose, nitrofurantoin 5 days)
- Complicated UTI: 5-7 days 7, 4
ESBL-Producing Enterobacterales UTIs
For uncomplicated UTIs caused by ESBL-producing organisms, oral options with high efficacy include nitrofurantoin (93% sensitivity), fosfomycin (98% sensitivity), and pivmecillinam (96% sensitivity for E. coli) 8.
These agents demonstrate >95% sensitivity against ESBL-producers and should be prioritized over carbapenems for mild-moderate infections 4, 8.
For complicated UTIs or when oral therapy fails:
- Preferred parenteral agents: Ceftazidime-avibactam 2.5g IV q8h, meropenem-vaborbactam 4g IV q8h, or imipenem-cilastatin-relebactam 1.25g IV q6h 7
- Alternative: Aminoglycosides (gentamicin 5-7 mg/kg/day IV once daily, amikacin 15 mg/kg/day IV once daily) 7
- Duration: 5-7 days 7
Carbapenem-sparing is achievable for uncomplicated ESBL UTIs using the oral agents above, reserving carbapenems for severe infections or treatment failures 4, 5.
MRSA Skin and Soft Tissue Infections
While the provided evidence doesn't contain specific MRSA skin infection guidelines, it emphasizes a critical principle: fluoroquinolones should not be used for MRSA due to rapid emergence of resistance during therapy 9. Historical data documents frequent development of quinolone-resistant MRSA strains either during or following fluoroquinolone treatment 9.
Standard MRSA treatment typically involves vancomycin, daptomycin, or linezolid based on infection severity and location (though specific dosing guidelines were not provided in the evidence for skin infections).
Key Fluoroquinolone Restrictions
Fluoroquinolones should be avoided as empiric therapy for UTIs and reserved only for confirmed susceptibility 4, 6. Recent surveillance shows trimethoprim resistance at 27% in some regions, with fluoroquinolone resistance similarly elevated 6. Their use against Gram-positive organisms, particularly MRSA and streptococci, is problematic due to rapid resistance emergence 9.
Acceptable fluoroquinolone use: Confirmed susceptibility in UTIs, or as part of guideline-recommended CAP regimens when no contraindications exist 1, 3.
New Agents Highlighted
β-lactam/β-lactamase inhibitor combinations for ESBL/carbapenem-resistant organisms:
- Ceftazidime-avibactam
- Meropenem-vaborbactam
- Imipenem-cilastatin-relebactam
- Ceftolozane-tazobactam 7, 5
Aminoglycosides: Plazomicin represents a newer option for resistant Gram-negatives 5.
Rediscovered agents: Fosfomycin, pivmecillinam, and nitrofurantoin have regained importance for ESBL UTIs 5, 8.
Treatment Duration Principles
The overarching stewardship principle is to use the shortest effective duration based on clinical stability 1, 2, 10. Approximately 85% of recent trials demonstrate equivalence or non-inferiority of shorter courses 10. However, severe infections (bloodstream infections, ventilator-associated pneumonia) require individualized approaches as evidence remains limited 10.